

JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA



RYAN I. YAMANE
DIRECTOR
KA LUNA HO'ŌKELE

JOSEPH CAMPOS II
DEPUTY DIRECTOR
KA HOPE LUNA HO'ŌKELE

STATE OF HAWAII
KA MOKU'ĀINA O HAWAI'I
DEPARTMENT OF HUMAN SERVICES
KA 'OIHANA MĀLAMA LAWELawe KANAKA
Med-QUEST Division
Clinical Standards Office
P. O. Box 700190
Honolulu, Hawaii 96709-0190

TRISTA SPEER
DEPUTY DIRECTOR
KA HOPE LUNA HO'ŌKELE

MINUTES OF MEETING
Med-QUEST Drug Use Review (DUR) Board

Date: Wednesday, February 11, 2026

Time: 12:00 P.M. (Noon)

Remote Meeting Location: Zoom Meeting participation for members and the public:
<https://medquest-hawaii-gov.zoom.us/j/83814701914?pwd=Gyd8f0EZxMGhFcp8udsNf0p7fXew00.1>

In-Person Location:
Kakuhihewa Building Conference Rooms 577A and 577B 601 Kamokila Blvd., Kapolei, Hawaii
96707

Members Present:

Dr. James Lumeng, Chair, Physician
Wendell Au, Vice-Chair, Pharmacist
Miki Lei Morita, Pharmacist
Kelsey Kong Trujillo, Pharmacist
Dr. Curtis Toma, Physician
Denise Oshiro, Pharmacist

Members Absent:

Dr. Greg Yuen
Reed Muraoka, Pharmacist

Staff present:

Erin Gomez, Clinical Standards Office (CSO) Office Assistant
Denise Oshiro, CSO DUR Coordinator Pharmacist
Dr. Curtis Toma, Medical Director
Ranjani Starr, CSO Administrator
Mike Mau, Systems Office (SO) Information Technology Specialist

MINUTES OF MEETING
Med-QUEST Drug Use Review (DUR) Board
February 2, 2026

Public Guests: Gary Peyton (Conduent), Herbert Starr (Acadia), Lori Howarth (Bayer), Hiten Patadia(Incyte), Chi Kohlhoff (Madrigal Pharmaceuticals), Christian Johnson (BioMarin Pharmaceuticals), Stefanie Abraham (Takeda), Lynda Finch(Biogen), Angie Adina mis (Otsuka), Don Robinson (Grifols USA), Lindsay Buck (Biogen), Matt Sheffield (Ascendis Pharma), William Lam (Madrigal), Miranda Ryzeman (Arita Solutions), Shawn Akey (Concis Labs),

- I. Board Denise Oshiro called the meeting to order at 12:10 pm. Dr. Curtis Toma introduced Denise Oshiro as the new pharmacy director. Denise Oshiro then proceeded with a roll call of the DUR Board members. Quorum was established with six members present. Introduction of the new DUR Board Member Kelsey Kong Trujillo. The board members participating were to declare if they were not alone. Each participating board members were able to declare they were alone except Denise Oshiro and Dr. Toma who were present in the meeting room.
- II. The August 14, 2024, meeting minutes were reviewed by the board. There was no public testimony. Without further discussion, it was moved by Dr. Curtis Toma to approve the minutes and seconded by Miki Morita. The motion passed unanimously, with no opposition and no abstentions. The May 14, 2025, minutes were reviewed by the board. There was no public testimony. Without further discussion, it was moved by Dr. Curtis Toma to approve the minutes and seconded by Miki Morita. The motion passed unanimously, with no opposition and no abstentions.
- III. New Business
 - a. Former Board member Eddie Fox, a medical service representative has retired from the board. Med-QUEST (MQD) is currently in communication with a medical service representative who is interested in joining the board.
 - b. In addition, there is an open Medicaid practicing board member position. Since the DUR Board focuses on FFS, and FFS covers members for dental services, a doctor of oral and maxillofacial surgery or the like is preferred, if available. MQD is requesting recommendations for this practicing physician board member position. No public testimony or board testimony was shared.
 - c. Under Hawai'i Administrative Rules MQD Dur Board members are appointed for a three-year term. MQD seeks interests from those current Board Members who are interested in retention for an extended three-year term, or less if retirement is near. MQD will submit names in a letter for approval by DHS Director Ryan Yamane. No public testimony or board testimony was shared.
 - d. Ultra high-cost drug Zolgensma for Spinal Muscular Atrophy will be carved back with the Managed Care Organizations (MCOs) effective January 1, 2026. This is because Zolgensma is among a dozen other high-cost medications now marketed, that are not carved out. Zolgensma is not a unique situation any longer. Also, MQD would like the MCOs to take back more ownership of drug therapy. Therefore, the actuary has factored Zolgensma back into the

MINUTES OF MEETING

Med-QUEST Drug Use Review (DUR) Board

February 2, 2026

capitation rate for each of the five MCOs as of January 1, 2026. No public testimony or board testimony was shared.

IV. Open Forum

- a. In-person and virtual attendees were given the opportunity for public testimony. However, there was no public testimony or board member testimony shared.

V. The next DUR Board meetings are: Wednesday, May 13, 2026, Wednesday, August 12, 2026, and Wednesday, November 18, 2026.

VI. Election of chairperson and vice-chairperson

- a. Public testimony was sought but none received.
- b. Dr. Toma nominated Dr. James Lumeng for the chairperson position. Wendell Au seconded the nomination. In the voting process all were in favor with none opposed.
- c. Ranjani Starr nominated Miki Morita for the vice-chairperson position. Dr. Toma seconded the nomination. In the voting process all were in favor with none opposed.
- d. The newly elected officials for chair Dr. James Lumeng and vice-chair Miki Morita were announced.

VII. Adjourn

- a. Dr. Toma motioned to adjourn the meeting and Wendell Au seconded the motion. The motion passed unanimously and no abstentions. The meeting was adjourned at 12:35 PM.

MINUTES OF MEETING
Med-QUEST Drug Use Review (DUR) Board
February 2, 2026